Status:
COMPLETED
Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic Hepatitis C Genotypes 1 Versus 2/3 Versus 6
Lead Sponsor:
Third Affiliated Hospital, Sun Yat-Sen University
Conditions:
Chronic Hepatitis C
Eligibility:
All Genders
16-65 years
Phase:
PHASE3
Brief Summary
The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. In this...
Eligibility Criteria
Inclusion
- HCV RNA is positive
- Treatment naive
- Come from China
Exclusion
- Active substance abuse
- Poorly controlled psychiatric disease
- HBsAg positive
- Anti-HIV positive
- Suffering from other significant concurrent medical conditions including chronic liver diseases
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2014
Estimated Enrollment :
535 Patients enrolled
Trial Details
Trial ID
NCT01433887
Start Date
November 1 2011
End Date
June 1 2014
Last Update
November 18 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
The Eighth People's Hospital of Guangzhou
Guangzhou, Guangdong, China, 510000
2
The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China, 510630
3
Zhongshan second people's hospital
Zhongshan, Guangdong, China